Orphan PAH Focus Target opportunities in Pulmonary Arterial Hypertension (PAH), an orphan indication, where Inhibikase is advancing IKT-001. Emphasize partnerships or trial support with contract research organizations and academic medical centers specializing in PAH to accelerate clinical development and potential commercialization plan.

Clinical Stage Momentum Leverage the ongoing IMPROVE-PAH Phase 3 program and recent site activations to position for collaborative trials, investigator-initiated studies, and outside funding opportunities. Highlight potential co-development or regional trial collaboration with CDMO partners and academic networks.

Strategic Financing The company has recent ATM financing and a substantial private placement history, signaling liquidity to support late-stage development. Approach specialty financiers, strategic investors, and partnering groups interested in PAH assets to explore co-development or milestone-based collaboration.

Leadership and Expertise New executive appointments in CFO, Chief Commercial and Strategy Officer, and clinical leadership suggest a push toward scalable commercialization planning. Engage with market access, payer strategy, and corporate development teams to align on pricing, reimbursement pathways, and launch readiness.

Market Positioning Imatinib-based PAH therapy with established safety data offers a compelling value proposition. Propose competitive intelligence support, real-world evidence generation ideas, and partnering opportunities with specialty pharma or biotechs seeking PAH portfolio expansion or orphan drug strategies.